Disease · MONDO_0001314

chondrocalcinosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chondrocalcinosis. Diseases, record MONDO_0001314. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001314

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chondrocalcinosis; Open Targets
Open Targets ID: MONDO_0001314; Open Targets
Other names: Calcium deposits in joints, calcium pyrophosphate deposition disease, pseudogout; Open Targets
Disease Ontology: DOID:1156; Disease Ontology
MeSH: D002805; MeSH
NCI Thesaurus: C34955; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 6 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
COLCHICINE	CHEMBL107	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BARICITINIB	CHEMBL2105759	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
HYDROXYCHLOROQUINE	CHEMBL1535	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TOCILIZUMAB	CHEMBL1237022	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PROBENECID	CHEMBL897	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets25

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
IL6R	Interleukin-6 receptor subunit alpha	1	Interleukin-6 receptor alpha subunit inhibitor	Phase 2	https://conductscience.org/library/genes/3570	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	1	Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Tyrosine-protein kinase JAK2	1	Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
SLC22A11	Solute carrier family 22 member 11	1	Solute carrier family 22 member 11 inhibitor	Early phase 1	https://conductscience.org/library/genes/55867	Drugs and targets
SLC22A6	Solute carrier family 22 member 6	1	Solute carrier family 22 member 6 inhibitor	Early phase 1	https://conductscience.org/library/genes/9356	Drugs and targets
SLC22A8	Organic anion transporter 3	1	Solute carrier family 22 member 8 inhibitor	Early phase 1	https://conductscience.org/library/genes/9376	Drugs and targets
TLR7	Toll-like receptor 7	1	Toll-like receptor 7 antagonist	Phase 2	https://conductscience.org/library/genes/51284	Drugs and targets
TLR9	Toll-like receptor 9	1	Toll-like receptor 9 antagonist	Phase 2	https://conductscience.org/library/genes/54106	Drugs and targets

1 to 10 of 25

See all 25 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02243631	Effect of Probenecid on Synovial Fluid ATP Levels in CPPD	Early phase 1	8	2022-07-26	Calcium Pyrophosphate Deposition Disease	PROBENECID	Its record names the disease	ClinicalTrials.gov
NCT06855433	Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment	Phase 2	150		CPPD - Calcium Pyrophosphate Deposition Disease	COLCHICINE	Its record names the disease	ClinicalTrials.gov
NCT07254637	Tocilizumab in Chronic Inflammatory CPPD Disease	Phase 2	80		Calcium Pyrophosphate Deposition Disease	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06768294	Baricitinib in CPPD - the BAPTIST Study	Phase 2	32		Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis	BARICITINIB, COLCHICINE, HYDROXYCHLOROQUINE, METHOTREXATE, METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Probenecid vs No Intervention: deaths from any cause	0 of 3	0 of 5	8	NCT02243631	Trial comparisons
Probenecid vs No Intervention: serious adverse events	0 of 3	0 of 5	8	NCT02243631	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001314

GET https://conductscience.org/api/diseases/v1/MONDO_0001314/targets?page=2

API reference For AI assistants